Endo shareholders approve combination with Mallinckrodt; deal targets close weeks after Irish court hearing

Endo LP

Transaction Proposal passed with 61,792,120 votes for (99.86%), 89,452 against.
Mallinckrodt also obtained shareholder approval; Irish High Court hearing expected in July.
Combined company will be headquartered in Dublin; Siggi Olafsson named CEO.
Plan to combine generics and sterile injectables, then separate later subject to board approval.

item 5.07item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.